Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 404, Issue 1, Pages 68-73Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2010.11.064
Keywords
EGFR; CBP; Acetylation; Phosphorylation; SAHA
Categories
Funding
- NIH [CA1109311, CA099031, CA126832, 1UL1RR024148]
- Breast Cancer SPORE [CA116199, CCSG CA16672]
- Patel Memorial Breast Cancer Research Fund
- MD Anderson Cancer Center-China Medical University
- Kadoorie Charitable Foundations
- [NSC97-3111-B-039]
- [NSC98-3111-B-039]
- [NHRI-EX98-9603BC]
- [DOH97-TD-I-111-TM003]
- [DOH 98-TD-I-111-TM002]
- [DOH97-TD-G-111-027]
- [DOH99-TD-C-111-005]
- [NSC99-2632-B-039-001-MY3]
Ask authors/readers for more resources
Alteration of epidermal growth factor receptor (EGFR) is involved in various human cancers and has been intensively investigated. A plethora of evidence demonstrates that posttranslational modifications of EGFR play a pivotal role in controlling its function and metabolism. Here, we show that EGFR can be acetylated by CREB binding protein (CBP) acetyltransferase. Interestingly, EGFR acetylation affects its tyrosine phosphorylation, which may contribute to cancer cell resistance to histone deacetylase inhibitors (HDACIs). Since there is an increasing interest in using HDACIs to treat various cancers in the clinic, our current study provides insights and rationale for selecting effective therapeutic regimen. Consistent with the previous reports, we also show that HDACI combined with EGFR inhibitors achieves better therapeutic outcomes and provides a molecular rationale for the enhanced effect of combination therapy. Our results unveil a critical role of EGFR acetylation that regulates EGFR function, which may have an important clinical implication. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available